Understanding the NIH’s New Indirect Cost Rate Policy: What Nonprofit and Higher Education CFOs Need to Know

Key Considerations for CFOs

1. Assessing the Financial Impact

NIH’s new policy could lead to significant funding shortfalls. CFOs should consider the following:

• Conduct financial modeling to quantify expected losses in indirect cost recovery.
• Identify high-risk programs that rely heavily on NIH funding.
• Determine cost absorption strategies to offset lost overhead recovery.
• Assess multi-year implications for ongoing research projects and infrastructure investments.

Example: A research university with a 55% negotiated IDC rate that receives $100 million annually in NIH grants would typically recover $55 million in indirect costs. Under the new 15% cap, that institution would receive only $15 million, leaving a $40 million funding gap per year.

2. The Impact on Fringe Benefit Rates

Many Research Institutions bundle fringe benefits (e.g., health insurance, retirement contributions, tuition benefits) into their indirect cost pools. With reduced IDC recovery, Research Institutions may have to:

• Increase fringe benefit rates on direct salaries to compensate for lost IDC funding.
• Reallocate benefit costs across other funding sources, potentially increasing financial strain.
• Evaluate whether reductions in employee benefits (e.g., retirement contributions, tuition reimbursement) are necessary to offset funding gaps.

Research Institutions should review their approach to fringe benefit cost and discuss with their internal team and outside IDC consultants to determine the best approach for their situation.

3. Operational and Compliance Challenges

• Managing Existing Grants: While the Notice explicitly applies the 15% cap to existing IHE grants moving forward, it is unclear whether NIH might apply it to other recipients (e.g., nonprofit research institutes). CFOs should seek clarification from NIH grant officers.
• Budgeting Adjustments: Departments reliant on indirect cost recovery will likely face budget cuts, hiring freezes, or program reductions.
• Regulatory Compliance: Research Institutions must ensure financial reporting and cost allocations comply with NIH’s new policy, particularly for multi-year grants awarded under higher negotiated rates.

4. Legal and Advocacy Considerations

The NIH policy faces multiple legal challenges, including claims that:

• The indirect cost rate reduction is arbitrary and capricious.
• The policy potentially violates Section 224 of the Further Consolidated Appropriations Act, 2024.
• NIH failed to follow required regulatory procedures before implementing the change.
• There is concern that NIH lacks the authority to alter negotiated rates on existing awards retroactively.

CFOs should:

• Monitor legal developments to anticipate potential policy changes.
• Engage in advocacy efforts through organizations such as:

• Council on Governmental Relations (COGR)
• Association of American Medical Colleges (AAMC)
• National Association of College and University Business Officers (NACUBO)

• Coordinate with government relations teams to provide data on institutional impact and support lobbying efforts.

5. Exploring Alternative Strategies

With IDC recovery limited to 15%, Research Institutions may need to:

• Renegotiate research agreements to shift costs to direct funding categories.
• Pursue alternative funding sources (e.g., industry partnerships, private grants).
• Restructure subawards to optimize financial recovery.
• Evaluate long-term capital planning to account for reduced overhead reimbursement.

Next Steps for CFOs

1. Conduct an immediate financial impact assessment to quantify potential losses.
2. Engage with NIH grant officers to clarify how the new policy applies to your institution.
3. Communicate with stakeholders (faculty, research administrators, leadership teams) about expected changes.
4. Join industry advocacy efforts to push for policy revisions or exemptions.
5. Develop contingency plans for future grant budgeting and indirect cost recovery strategies.
6. Stay informed on legal developments that could affect the policy’s implementation.

UPDATE: 2/24/2025

Legal Ruling on NIH Indirect Cost Reimbursement Policy

In early February 2025, the National Institutes of Health (NIH) announced a policy to cap indirect cost reimbursements at 15% for all new and existing research grants, effective February 10, 2025. This policy represents a significant reduction from previously negotiated rates, which averaged between 27% and 28%, with some institutions receiving rates exceeding 50%. Indirect costs, also known as facilities and administrative costs, cover essential expenses such as laboratory maintenance, utilities, and administrative support necessary for conducting research.